Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

American Journal of Medicine

Volumn 100, Issue 4, 1996, Pages 452-455

  Cortes, Jorge ^a   Kantarjian, Hagop ^a,b   O'Brien, Susan ^a   Robertson, L E ^a   Pierce, Sherry ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON; ANTINEOPLASTIC AGENT; GAMMA INTERFERON;

AGED; AGING; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DATA ANALYSIS; DOSE RESPONSE; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS; SURVIVAL RATE; AGE; BASOPHIL; BONE MARROW; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FOLLOW UP; MIDDLE AGED; MYELOID LEUKEMIA; NEUROLOGIC DISEASE; PATHOLOGY; UNITED STATES;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BASOPHILS; BONE MARROW; CHRONIC DISEASE; FATIGUE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; INTERFERON TYPE II; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; REMISSION INDUCTION; SURVIVAL RATE; TEXAS;

EID: 0029664772     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89522-8     Document Type: Article

References (20)

1. Kantarjian H, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia-chromosome positive leukemias. NEJM. 1988;319:990-998.
3. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busutfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood. 1993;83:398-407.
4. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155.
5. Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. NEJM. 1986;314;202.
6. Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood. 1992;80:1352-1357.
7. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-2043.
8. Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med. 1991;114:532-538.
9. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival following achievement of a cytogenetic response with alpha interferon therapy in chronic myelogenous leukemia. Ann Intern Med. 1995;122:254-261.
10. Cortes J, Talpaz M, Beran M, et al. Philadelphia-chromosome negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region: long-term follow-up results. Cancer. 1995;75:464-470.
11. A in chronic myelogenous leukemia. NEJM. 1986;314:1065-1069.
12. Trujillo JM, Cork A, Ahern MJ, et al. Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood. 1979;53:695-706.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Cox DR, Regression models and life tables. J Royal Stat Soc. 1972;34:187-220.
15. Kantarjian HM, Keating MJ, Smith TL, et al. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88:1-8.
16. Brincker H. Population-based age-and sex-specific incidence rates in the 4 main types of leukemia. Scan J Haematol. 1982;29:241-249.
17. Baranovsky A, Myers MH. Cancer incidence and survival in patients 65 years of age and older. CA Cancer J Clin. 1986;36:26-41.
18. Kantarjian HM, Shtalrid M, Kurzrock R, et al. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med. 1988;85:639-644.
19. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of the interferons in cancer patients: a review, J Clin Oncol. 1986;4:234-243.
20. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994;121:736-744.